ProQR Announces Presentations at the European CF Conference and the JMP Life Science Conference Press release LEIDEN, the Netherlands, June 01, 2016 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. juin 01, 2016
ProQR Announces the Grant of two Key Patents, protecting QR-010 for Cystic Fibrosis in the US and EU Press release … from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 633545. … avril 03, 2017
ProQR Presents in vivo Proof of Concept Data for the Axiomer® RNA Editing Platform Technology Press release Key updates septembre 21, 2017
ProQR Announces Clinical Data Presentations and Investor & Analyst Event at NACFC Press release … from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 633545. … septembre 27, 2016
ProQR Receives Fast Track Designation from FDA for QR-010 for Cystic Fibrosis Press release LEIDEN, the Netherlands, July 19, 2016 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. juillet 19, 2016
ProQR Appoints David M. Rodman, MD as Chief Development Strategy Officer Press release … Officer of ProQR. “Between Gerard (Platenburg, Chief Innovation Officer), Dave and Noreen we cover all key … mars 27, 2017
ProQR Announces Management Change and Key Promotions Press release … development. Dr. Friesen has served as Head of Innovation at the Company since June 2016. He obtained a M.S. … octobre 26, 2017
ProQR Completes Dosing of Cystic Fibrosis Patients in QR-010 Phase 1b Trial Press release Key Updates août 29, 2017
ProQR to present QR-010 data at the European Cystic Fibrosis Society Conference and provides an update on the ongoing Phase 1b trial Press release … central European time in Sevilla, Spain. “QR-010 is an innovative approach to restoring CFTR function in patients … from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 633545. About … juin 08, 2017
ProQR to Release Topline Data from Proof of Concept Study of QR-010 in Cystic Fibrosis Patients at NACFC Press release LEIDEN, the Netherlands, June 21, 2016 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. juin 21, 2016